🚨ICYMI - Updated Cochrane #SystematicReview:
Withdrawal of antihypertensive drugs in older people 💊
doi.org/10.1002/1465...
"Future research should focus on populations with the greatest uncertainty of the benefit:risk ratio"
#CochraneEvidence #bloodpressure #deprescribing
🌍 Antihypertensives are among the commonly prescribed medications globally.
Read about a recently-published systematic review & meta-analysis on #deprescribing antihypertensive medications in older people, conducted together with our collaborators here:
buff.ly/CPznF05
🆕 Cochrane #hypertension review:
#Riboflavin supplements for blood pressure lowering in adults
www.cochranelibrary.com/cdsr/doi/10....
🤔 Very uncertain evidence for effect of riboflavin on #bloodpressure
🎯 Large, well‐conducted trials needed
#SystematicReviews #CochraneEvidence
Too good to be true? Spotting problematic trials in systematic reviews | Online
🗓️26 February
This interactive webinar will introduce the INSPECT-SR tool by way of application to a published clinical trial.
🔗Register here: evidencesynthesisireland.ie/conference/w...
🚨ICYMI - Updated Cochrane #SystematicReview:
Withdrawal of antihypertensive drugs in older people 💊
doi.org/10.1002/1465...
"Future research should focus on populations with the greatest uncertainty of the benefit:risk ratio"
#CochraneEvidence #bloodpressure #deprescribing
🆕Review update🆕
Pharmacotherapy for mild #hypertension cochranelibrary.com/cdsr/doi/10....
In people with mildly elevated #BloodPressure (BP) without cardiovascular disease (CVD) or related health risks, BP meds may not reduce risk of death or of developing major CVD
#SystematicReview
🆕 @cochrane.org Review update 🆕
Pharmacotherapy for mild hypertension www.cochranelibrary.com/cdsr/doi/10....
In ppl w/ mildly elevated blood pressure (BP) w/out cardiovascular disease (CVD) or related health risks, BP meds may not reduce risk of death or of developing major CVD
#SystematicReview
Cochrane logo on a blue background with the text 'Cochrane aligns reporting formats for diverse types of reviews.' Below, a stack of books on a table in a library setting conveys a scholarly tone.
Clearer, more consistent Cochrane reviews are coming.
From mid-November, we’re updating reporting formats to make reviews easier to use, more accessible, and more impactful.
🔗 www.cochrane.org/about-us/new...
Too good to be true? Spotting problematic trials in systematic reviews | Online
🗓️ 26 February
This interactive webinar will introduce the INSPECT-SR tool by way of application to a published clinical trial.
🔗 evidencesynthesisireland.ie/conference/w...
Getting involved in health research reviews: a course for the public | Online
🗓️ 15 September
Are you a patient, caregiver, or member of the public interested in contributing to health research? This 6-week, self-paced course from Cochrane Ireland is for you.
🔗 www.eventbrite.ie/e/getting-in...
📣 We're rounding up a few dates for your diary. Discover these events being run by our global network of Cochrane Groups – a thread 🧵
ICYMI - Cochrane #SystematicReview 🎺
Renin inhibitors versus angiotensin receptor blockers for primary #hypertension
doi.org/10.1002/1465...
#CochraneEvidence #Blogshot
🚨ICYMI - Updated Cochrane #SystematicReview:
Withdrawal of antihypertensive drugs in older people 💊
doi.org/10.1002/1465...
"Future research should focus on populations with the greatest uncertainty of the benefit:risk ratio"
#CochraneEvidence #bloodpressure #deprescribing
Also check out our complementary #deprescribing resources to reduce potentially inappropriate medications found here:
deprescribing.org/resources/de...
🚨ICYMI - Updated Cochrane #SystematicReview:
Withdrawal of antihypertensive drugs in older people 💊
doi.org/10.1002/1465...
"Future research should focus on populations with the greatest uncertainty of the benefit:risk ratio"
#CochraneEvidence #bloodpressure #deprescribing
🆕 We've published a new Cochrane #SystematicReview protocol:
Blood pressure lowering efficacy of dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonists compared to glucagon-like peptide-1 (GLP-1) receptor agonists
doi.org/10.1002/1465...
SR & MA findings: very few (<10%) clinical trials report adverse drug withdrawal event (ADWE) following #deprescribing, and reporting methods are inconsistent.
Standardizing reporting is needed to generate more robust evidence on deRXing and ADWEs: agsjournals.onlinelibrary.wiley.com/doi/10.1111/...
🚨 ICYMI - TI #BestEvidence webinar:
Dr. Josh Levin compares #PhysicalActivity to drugs for important clinical outcomes
ti.ubc.ca/drugevidence24
#DrugEvidence24 #exercise #MedEd
ICYMI: #BestEvidence webinar recording
Debunking some of the hype in #hypertension
ti.ubc.ca/drugevidence24
Dr. James Wright summarizes latest evidence on #antihypertensives
⏰ chronotherapy
💊 first line tx
🎯 BP targets
⚠️ tx efficacy + safety
#DrugEvidence24 #MedEd #medsafety
🚨Updated Cochrane #SystematicReview:
Withdrawal of antihypertensive drugs in older people 💊
doi.org/10.1002/1465...
"Future research should focus on populations with the greatest uncertainty of the benefit:risk ratio"
#CochraneEvidence #bloodpressure #deprescribing
🧵 #ExercisePrescriptions
1/5 The TI’s Dr. Josh Levin asks:
Clinicians, can you help your patients be more active? 🏃🏾♀️🏊🏾♂️ 🚶🏾♂️
👉🏾Watch Dr. Levin’s presentation: www.youtube.com/watch?v=G5he...
#Exercise #prescribing #ExerciseRx
🆕 Cochrane #SystematicReview 🆕
Effect of adrenergic agonist oral #decongestants on blood pressure:
www.cochranelibrary.com/cdsr/doi/10....
#CochraneEvidence #blogshot #bloodpressure
🆕 Cochrane #SystematicReview 🆕
Effect of #amphetamines on blood pressure:
www.cochranelibrary.com/cdsr/doi/10....
#CochraneEvidence #blogshot #bloodpressure
ICYMI - Cochrane #SystematicReview 🎺
Renin inhibitors versus angiotensin receptor blockers for primary #hypertension
doi.org/10.1002/1465...
#CochraneEvidence #Blogshot
🚨ICYMI - Cochrane #SystematicReview
Renin inhibitors versus angiotensin receptor blockers for primary #hypertension
doi.org/10.1002/1465...
#CochraneEvidence #Blogshot
Cochrane #SystematicReview 🎺
Renin inhibitors versus angiotensin receptor blockers for primary #hypertension
doi.org/10.1002/14651858.CD012570.pub2
#CochraneEvidence #Blogshot
#BestEvidence webinar recording
Debunking some of the hype in #Hypertension
ti.ubc.ca/drugevidence24
Dr. James Wright summarizes latest evidence on #antihypertensives:
⏰ chronotherapy
💊 first line tx
🎯 blood pressure targets
⚠️ treatment efficacy + safety
#drugevidence24 #meded #medsafety
🎺 Cochrane #SystematicReview 🚨
Renin inhibitors versus angiotensin receptor blockers for primary #hypertension
tinyurl.com/renin-arb-htn
#CochraneEvidence #Blogshot @drotte.medsky.social @ciprian-jauca.bsky.social @amtejani.bsky.social
🎺 Cochrane #SystematicReview 🚨
Renin inhibitors versus angiotensin receptor blockers for primary #hypertension
doi.org/10.1002/1465...
#CochraneEvidence #Blogshot
🆕 Cochrane #SystematicReview 🎺
Renin inhibitors versus angiotensin receptor blockers for primary #hypertension
doi.org/10.1002/1465...
#CochraneEvidence
